Raloxifene is a benzothiophene SERM with distinct tissue-selective ER modulation profile compared to tamoxifen. Acts as ER antagonist in breast and uterus — critically, without the partial uterine agonism seen with tamoxifen (no endometrial proliferation risk). Acts as ER agonist in bone (preserves BMD) and lipid metabolism (reduces LDL). This superior tissue selectivity profile makes raloxifene unique among SARMs for models where uterine safety is relevant. Also studied for gynecomastia where its lack of uterine agonism is advantageous.
STAR trial (N=19,747): raloxifene vs tamoxifen in high-risk postmenopausal women — equivalent invasive BC risk reduction, 36% less uterine cancer risk vs tamoxifen. Defines superior uterine safety profile for SERM prevention research.
Osteoporosis / Bone Density Research
MORE trial: raloxifene 60mg vs placebo in postmenopausal osteoporosis — vertebral fracture risk reduced 30-50%. ER agonism in bone via ERα in osteoblasts. Reference second-gen SERM for bone research with no proliferative uterine effects.
Gynecomastia Research
Raloxifene vs tamoxifen in pubertal and adult gynecomastia: comparable breast tissue ER antagonism, no uterine stimulation, different metabolic profile. Dose-response data published for raloxifene in gynecomastia models.
Lipid / Cardiovascular Research
Raloxifene ER agonism in liver reduces LDL-C (similar to oestrogen) without triglyceride elevation. RUTH trial cardiovascular outcomes data. Reference compound for SERM cardiovascular research.
Key Research Data
Study / Source
Key Findings
STAR Trial 2006 JAMA
N=19,747: raloxifene vs tamoxifen prevention — equivalent invasive BC risk reduction, superior uterine cancer safety, fewer DVT events
MORE Trial 1999 JAMA
Raloxifene in postmenopausal osteoporosis: 30-50% vertebral fracture reduction, BMD preservation — bone SERM reference data
RUTH Trial 2006 NEJM
Raloxifene cardiovascular outcomes — LDL reduction, no CV benefit in high-risk women, DVT risk noted
Specifications
Format
Oral tablet — 50mg per tablet
Purity
≥99% HPLC
Identity
MS confirmed
Storage
Room temperature
vs Tamoxifen
No uterine agonism, no endometrial risk — superior uterine safety profile
Frequently Asked Questions
What is Raloxifene (Evista)?
Raloxifene (Evista) is a Selective Oestrogen Receptor Modulator (SERM) — second-generation. Raloxifene is a benzothiophene SERM with distinct tissue-selective ER modulation profile compared to tamoxifen. Acts as ER antagonist in breast and uterus — critically, without the partial uterine agonism seen with tamoxifen (no endometrial prolifera…
How does Raloxifene work in research models?
STAR trial (N=19,747): raloxifene vs tamoxifen in high-risk postmenopausal women — equivalent invasive BC risk reduction, 36% less uterine cancer risk vs tamoxifen. Defines superior uterine safety profile for SERM prevention research….
What makes Raloxifene different from similar compounds?
MORE trial: raloxifene 60mg vs placebo in postmenopausal osteoporosis — vertebral fracture risk reduced 30-50%. ER agonism in bone via ERα in osteoblasts. Reference second-gen SERM for bone research with no proliferative uterine effects….
Does QSC ship Raloxifene to the USA?
Yes. QSC Raloxifene ships domestically across the USA and internationally to EU, UK, Canada, and Australia. Every batch carries a Janoshik third-party COA confirming ≥99% HPLC purity and MS identity verification.
